论文部分内容阅读
目的:探讨Wnt信号通路拮抗剂分泌型卷曲相关蛋白1(SFRP1)和分泌型卷曲相关蛋白2(SFRP2)在肾细胞癌组织中的表达及其意义。方法:采用免疫组织化学方法对55例肾细胞癌组织及15例癌旁正常肾组织的SFRP1、SFRP2表达情况进行检测,初步探讨两者与肾细胞癌生物学特性的关系。结果:SFRP1和SFRP2在癌旁肾组织中较肾细胞癌组织明显增高(P<0.01)。SFRP1和SFRP2阳性表达率在不同组织学类型的肾细胞癌中差异无统计学意义(P>0.05)。SFRP1和SFRP2表达主要与病理分期、肿瘤细胞分级有关(P<0.05),而与患者年龄、性别、肿瘤直径及临床表现无关(P>0.05)。在肾细胞癌中,SFRP1与SFRP2表达具有相关性。应用Spearman相关检验分析得出:SFRP1表达与SFRP2表达呈正相关(r=0.392,P=0.003)。结论:Wnt信号通路拮抗剂SFRP1和SFRP2在RCC中表达下调或减弱,SFRP1、SFRP2可能为预防RCC及RCC早期诊断和预后评估提供新思路。
Objective: To investigate the expression and significance of Wnt signaling pathway antagonist secreted type 1 (SFRP1) and secreted type 2 (SFRP2) proteins in renal cell carcinoma. Methods: The expressions of SFRP1 and SFRP2 in 55 cases of renal cell carcinoma and 15 cases of adjacent normal renal tissues were detected by immunohistochemistry. The relationship between them and the biological characteristics of renal cell carcinoma was discussed. Results: The expression of SFRP1 and SFRP2 in renal allograft tissues was significantly higher than that in renal cell carcinoma (P <0.01). The positive rates of SFRP1 and SFRP2 in different histological types of renal cell carcinoma showed no significant difference (P> 0.05). The expression of SFRP1 and SFRP2 was mainly associated with pathological stage and tumor cell classification (P <0.05), but not with age, gender, tumor diameter and clinical manifestations (P> 0.05). In renal cell carcinoma, there is a correlation between SFRP1 and SFRP2 expression. Spearman correlation analysis showed that SFRP1 expression was positively correlated with SFRP2 expression (r = 0.392, P = 0.003). CONCLUSIONS: Wnt signaling pathway antagonists SFRP1 and SFRP2 are down-regulated or down-regulated in RCC. SFRP1 and SFRP2 may provide new ideas for preventing early diagnosis and prognosis of RCC and RCC.